Both Viibryd and Cope offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Both Viibryd and Cope have similar safety profiles, with mild and transient side effects. Neither presents significant long-term safety concerns.

Viibryd has a lower risk of dependency, making it a safer option for patients concerned about addiction.

Viibryd offers the convenience of a once-daily dose, simplifying treatment adherence for patients.

Viibryd has fewer contraindications, making it suitable for a broader range of patients, including those with comorbidities.

Viibryd is ideal for patients needing quick relief and higher potency. It’s easier to use, safer for most patients, and has a lower addiction risk, making it a top choice for acute symptoms.